| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0140-6736(16)30172-6 |
| P698 | PubMed publication ID | 27240885 |
| P50 | author | Cosimo Durante | Q62668178 |
| P2093 | author name string | Maria E Cabanillas | |
| David G McFadden | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer | Q24596266 | ||
| The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis | Q26996642 | ||
| Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations | Q27853199 | ||
| Pax-8-PPAR-γ fusion protein in thyroid carcinoma | Q28244806 | ||
| Integrated genomic characterization of papillary thyroid carcinoma | Q28251986 | ||
| Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer | Q28262641 | ||
| BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study | Q28289851 | ||
| 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer | Q30367068 | ||
| BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis | Q31032245 | ||
| Nonsurgical approaches to the management of thyroid nodules | Q33255234 | ||
| Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012 | Q33570297 | ||
| TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer | Q33682388 | ||
| Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. | Q33995708 | ||
| Cabozantinib in progressive medullary thyroid cancer | Q34185084 | ||
| TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas | Q34313648 | ||
| A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer | Q34330748 | ||
| Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma | Q34468665 | ||
| An observational trial for papillary thyroid microcarcinoma in Japanese patients | Q34615004 | ||
| Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation | Q34714310 | ||
| Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. | Q34716574 | ||
| Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience | Q34810764 | ||
| RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). | Q53164620 | ||
| Sonographic features of follicular variant papillary thyroid carcinomas in comparison with conventional papillary thyroid carcinomas. | Q53489281 | ||
| Diagnosis of thyroid follicular carcinoma by the vascular pattern and velocimetric parameters using high resolution pulsed and power Doppler ultrasonography. | Q53859164 | ||
| Multicenter clinical experience with the Afirma gene expression classifier. | Q54706749 | ||
| Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. | Q55067769 | ||
| Predictive factors of malignancy in thyroid nodules with a cytological diagnosis of follicular neoplasm | Q57223578 | ||
| American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer | Q57793991 | ||
| Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma | Q73802829 | ||
| Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer | Q78815058 | ||
| Outcomes of patients with differentiated thyroid carcinoma following initial therapy | Q79472924 | ||
| Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer | Q79819385 | ||
| Clinical evaluation of color Doppler imaging for the differential diagnosis of thyroid follicular lesions | Q80938904 | ||
| Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer | Q81566849 | ||
| Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy | Q82039906 | ||
| Subclinical thyroid disease | Q83315660 | ||
| Medullary thyroid carcinoma: management of lymph node metastases | Q84284653 | ||
| Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? | Q84330193 | ||
| Recurrence after treatment of micropapillary thyroid cancer | Q84579175 | ||
| The Bethesda System for reporting thyroid fine-needle aspiration specimens | Q84595717 | ||
| Management of papillary thyroid cancer patients in absence of postoperative radioiodine remnant ablation: tailoring follow-up by neck sonography | Q84603601 | ||
| Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer | Q84670448 | ||
| A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes | Q85954152 | ||
| Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases | Q86069282 | ||
| Surgical utility of Afirma: effects of high cancer prevalence and oncocytic cell types in patients with indeterminate thyroid cytology | Q86774284 | ||
| Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons | Q88107398 | ||
| Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer | Q94332426 | ||
| BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer | Q34919430 | ||
| Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. | Q35023367 | ||
| Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial | Q35195766 | ||
| Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples | Q35497850 | ||
| Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients | Q35940198 | ||
| Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology | Q36297926 | ||
| Thyroid-hormone therapy and thyroid cancer: a reassessment | Q36575425 | ||
| Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Associat | Q36837469 | ||
| Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial | Q36910409 | ||
| Wide Inter-institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules | Q37044573 | ||
| Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. | Q37149600 | ||
| Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer | Q37216703 | ||
| Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer | Q37275937 | ||
| Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis | Q37413348 | ||
| Risk of thyroid cancer based on thyroid ultrasound imaging characteristics: results of a population-based study | Q37607015 | ||
| The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer | Q37650515 | ||
| Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer | Q37660065 | ||
| Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes | Q37672389 | ||
| Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer | Q37869194 | ||
| Molecular genetics and diagnosis of thyroid cancer | Q37924088 | ||
| Preoperative diagnosis of benign thyroid nodules with indeterminate cytology | Q38021490 | ||
| The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. | Q38053499 | ||
| The utility of routine preoperative cervical ultrasonography in patients undergoing thyroidectomy for differentiated thyroid cancer | Q38134955 | ||
| Thyroid Gland Malignancies | Q38633651 | ||
| Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer? | Q39091785 | ||
| The increasing incidence of small thyroid cancers: Where are the cases coming from? | Q39813346 | ||
| Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study. | Q39988308 | ||
| The natural history of benign thyroid nodules. | Q41312346 | ||
| Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. | Q42190157 | ||
| Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma | Q43719871 | ||
| Papillary thyroid cancer: time course of recurrences during postsurgery surveillance | Q44733673 | ||
| Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. | Q45223795 | ||
| Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients | Q45824028 | ||
| Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer | Q46084955 | ||
| Surgery for papillary thyroid carcinoma: is lobectomy enough? | Q46794598 | ||
| Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis | Q46911892 | ||
| Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma | Q50092862 | ||
| An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules | Q50120888 | ||
| Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. | Q51226659 | ||
| Clinical and cytological features predictive of malignancy in thyroid follicular neoplasms. | Q51765341 | ||
| P433 | issue | 10061 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2783-2795 | |
| P577 | publication date | 2016-05-27 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Thyroid cancer | |
| P478 | volume | 388 |
| Q90203005 | A Rare Coexistence of Medullary Thyroid Cancer with Graves Disease: A Case Report and Systematic Review of the Literature |
| Q90777990 | ANGPTL4 Promotes the Proliferation of Papillary Thyroid Cancer via AKT Pathway |
| Q55363491 | Activity of roniciclib in medullary thyroid cancer. |
| Q90124427 | African Head and Neck Society Clinical Practice guidelines for thyroid nodules and cancer in developing countries and limited resource settings |
| Q103031352 | Ambulatory thyroidectomy is safe and beneficial in papillary thyroid carcinoma: Randomized controlled trial |
| Q97420258 | Anaplastic thyroid cancer: How far can we go? |
| Q61799892 | Antitumor Effect of Various Phytochemicals on Diverse Types of Thyroid Cancers |
| Q90382919 | Autophagy Function and Dysfunction: Potential Drugs as Anti-Cancer Therapy |
| Q92016972 | BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis |
| Q91756449 | BRAFV600E-induced KRT19 expression in thyroid cancer promotes lymph node metastasis via EMT |
| Q55262954 | CITED1 gene promotes proliferation, migration and invasion in papillary thyroid cancer. |
| Q59137522 | CITED1 promotes proliferation of papillary thyroid cancer cells via the regulation of p21 and p27 |
| Q59340778 | CMTCN: a web tool for investigating cancer-specific microRNA and transcription factor co-regulatory networks |
| Q55362221 | CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer. |
| Q97885898 | Cancer Care During COVID-19 Era: The Quality of Life of Patients With Thyroid Malignancies |
| Q89719101 | Circular RNA Profiling Reveals Exosomal circ_0006156 as a Novel Biomarker in Papillary Thyroid Cancer |
| Q91790996 | Clinical roles of miR-136-5p and its target metadherin in thyroid carcinoma |
| Q59137538 | Clinicopathological characteristics and prognosis of thyroid cancer in northwest China: A population-based retrospective study of 2490 patients |
| Q90292723 | Computed Tomography Radiomic Nomogram for Preoperative Prediction of Extrathyroidal Extension in Papillary Thyroid Carcinoma |
| Q55144990 | Current role of interventional radiology in the management of visceral and bone metastases from thyroid cancer. |
| Q64279385 | Development of a risk scoring system for patients with papillary thyroid cancer |
| Q90481060 | Effect of miR-205 on proliferation and migration of thyroid cancer cells by targeting CCNB2 and the mechanism |
| Q48190761 | Effects of nutraceuticals on anaplastic thyroid cancer cells |
| Q95654463 | Endocrine surgery during and after the COVID-19 epidemic: Expert guidelines from AFCE |
| Q64086580 | Epigallocatechin-3-gallate inhibits the growth and increases the apoptosis of human thyroid carcinoma cells through suppression of EGFR/RAS/RAF/MEK/ERK signaling pathway |
| Q64231739 | Expression of Leptin Receptor and Effects of Leptin on Papillary Thyroid Carcinoma Cells |
| Q48315201 | Expression of YAP1 in aggressive thyroid cancer |
| Q50044107 | Fast-growing cervical mass: anaplastic thyroid carcinoma |
| Q33593910 | Fluorescence in situ hybridization in surgical pathology: principles and applications |
| Q90699489 | Follow-up of differentiated thyroid cancer - what should (and what should not) be done |
| Q58730241 | Glycosylation in the Thyroid Gland: Vital Aspects of Glycoprotein Function in Thyrocyte Physiology and Thyroid Disorders |
| Q99625021 | Hsa_circRNA_102002 facilitates metastasis of papillary thyroid cancer through regulating miR-488-3p/HAS2 axis |
| Q89819678 | Hsa_circ_0011385 accelerates the progression of thyroid cancer by targeting miR-361-3p |
| Q92029927 | Hsa_circ_0058124 promotes papillary thyroid cancer tumorigenesis and invasiveness through the NOTCH3/GATAD2A axis |
| Q92644737 | IGFBP7 inhibits cell proliferation by suppressing AKT activity and cell cycle progression in thyroid carcinoma |
| Q90471453 | Identification and Validation of Core Genes Involved in the Development of Papillary Thyroid Carcinoma via Bioinformatics Analysis |
| Q96231220 | Identification and validation of m6A RNA methylation regulators with clinical prognostic value in Papillary thyroid cancer |
| Q91992301 | Identification of Key Genes in Thyroid Cancer Microenvironment |
| Q91707657 | Identification of a Five-Gene Signature and Establishment of a Prognostic Nomogram to Predict Progression-Free Interval of Papillary Thyroid Carcinoma |
| Q48114853 | Imaging of Anaplastic Thyroid Carcinoma |
| Q64080240 | Immediate Surgery Might Be a Better Option for Subcapsular Thyroid Microcarcinomas |
| Q47154093 | Inhibition of X-linked inhibitor of apoptosis protein suppresses tumorigenesis and enhances chemosensitivity in anaplastic thyroid carcinoma |
| Q89771439 | Investigation of promoter methylation of FSCN1 gene and FSCN1 protein expression in differentiated thyroid carcinomas |
| Q90550404 | Isthmusectomy in selected patients with well-differentiated thyroid carcinoma |
| Q90002242 | KIAA1199, a Target of MicoRNA-486-5p, Promotes Papillary Thyroid Cancer Invasion by Influencing Epithelial-Mesenchymal Transition (EMT) |
| Q89737460 | Knockdown of Thymidine Kinase 1 Suppresses Cell Proliferation, Invasion, Migration, and Epithelial-Mesenchymal Transition in Thyroid Carcinoma Cells |
| Q88393333 | Lack of association between obesity and aggressiveness of differentiated thyroid cancer |
| Q41622158 | Langerhans cell histiocytosis of the thyroid complicated by papillary thyroid carcinoma: A case report and brief literature review |
| Q64265653 | Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review |
| Q64073094 | Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment |
| Q89538431 | LncRNA WT1-AS Downregulates Survivin by Upregulating miR-203 in Papillary Thyroid Carcinoma |
| Q92680670 | Long noncoding RNA CASC9 promotes the proliferation and metastasis of papillary thyroid cancer via sponging miR-488-3p |
| Q90087519 | Low expression of ryanodine receptor 2 is associated with poor prognosis in thyroid carcinoma |
| Q42666368 | MiR-150 Inhibits Cell Growth In Vitro and In Vivo by Restraining the RAB11A/WNT/β-Catenin Pathway in Thyroid Cancer. |
| Q64108364 | MicroRNA-221 promotes papillary thyroid carcinoma cell migration and invasion via targeting RECK and regulating epithelial-mesenchymal transition |
| Q42361202 | MicroRNAs as Biomarkers in Thyroid Carcinoma. |
| Q91761497 | Microfluidic Droplet Digital PCR Is a Powerful Tool for Detection of BRAF and TERT Mutations in Papillary Thyroid Carcinomas |
| Q90194104 | Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice |
| Q48088782 | Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation |
| Q92153333 | Multikinase Inhibitor Treatment in Thyroid Cancer |
| Q64058147 | Mutation profiles of follicular thyroid tumors by targeted sequencing |
| Q58784257 | Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond |
| Q97524196 | New proposed tumor-node-metastasis staging system for medullary thyroid carcinoma based on the Surveillance, Epidemiology, and End Results database |
| Q58550783 | Not the same thing: metastatic PTCs have a different background than ATCs |
| Q47797352 | Outcome prediction with the revised American joint committee on cancer staging system and American thyroid association guidelines for thyroid cancer. |
| Q89964097 | Polymer Nanoformulation of Sorafenib and All-Trans Retinoic Acid for Synergistic Inhibition of Thyroid Cancer |
| Q37657386 | Potential Antitumor Effect of Harmine in the Treatment of Thyroid Cancer. |
| Q90698156 | Potential synergistic effects of sorafenib and CP-31398 for treating anaplastic thyroid cancer with p53 mutations |
| Q91655787 | Predicting factors of lateral neck lymph node metastases in patients with papillary thyroid microcarcinoma |
| Q94527879 | Predictive factors for central lymph node metastases in papillary thyroid microcarcinoma |
| Q90636860 | Preoperative Sonographic and Clinicopathological Predictors for Solitary Lateral Neck Node Metastasis in Papillary Thyroid Carcinoma: A Retrospective Study |
| Q90216816 | Progression of Thyroid Carcinoma Is Promoted by the m6A Methyltransferase METTL3 Through Regulating m6A Methylation on TCF1 |
| Q97524393 | Proto-oncogene RTL4 promotes tumorigenesis and invasiveness of papillary thyroid cancer |
| Q48109260 | Recent advances in managing differentiated thyroid cancer |
| Q90570602 | Resource Utilization and Costs in Adolescents Treated for Cancer in Pediatric vs Adult Institutions |
| Q38600499 | Restratification of survival prognosis of N1b papillary thyroid cancer by lateral lymph node ratio and largest lymph node size. |
| Q89704631 | Resveratrol Inhibits the Tumorigenesis of Follicular Thyroid Cancer via ST6GAL2-Regulated Activation of the Hippo Signaling Pathway |
| Q52622186 | Resveratrol Suppresses the Growth and Enhances Retinoic Acid Sensitivity of Anaplastic Thyroid Cancer Cells. |
| Q99611217 | Risk Factors for Lateral Lymph Node Metastases in Patients With Sporadic Medullary Thyroid Carcinoma |
| Q64085391 | Role of Emerging Environmental Risk Factors in Thyroid Cancer: A Brief Review |
| Q89475525 | SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms |
| Q38719594 | Selective Ablation of Tumor Suppressors in Parafollicular C Cells Elicits Medullary Thyroid Carcinoma |
| Q56815367 | Semantic Analysis of Posttranslational Modification of Proteins Accumulated in Thyroid Cancer Cells Exposed to Simulated Microgravity |
| Q64270851 | Senescent thyrocytes and thyroid tumor cells induce M2-like macrophage polarization of human monocytes via a PGE2-dependent mechanism |
| Q57807464 | Shear wave elastography in the evaluation of level VI lymph nodes in papillary thyroid carcinoma: combined with gray-scale ultrasound ex vivo |
| Q92545532 | Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma |
| Q47259025 | Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor-β type I receptor/apoptosis signal-regulating kinase 1/mitogen-activated protein kinase signaling axis. |
| Q46170145 | Sonic Hedgehog Signaling in Thyroid Cancer |
| Q55209659 | Steroid receptor coactivator-1 interacts with NF-κB to increase VEGFC levels in human thyroid cancer. |
| Q99583209 | Synergic effects of histology subtype, lymph node metastasis, and distant metastasis on prognosis in differentiated thyroid carcinoma using the SEER database |
| Q58782084 | TIPE2 acts as a biomarker for tumor aggressiveness and suppresses cell invasiveness in papillary thyroid cancer (PTC) |
| Q91863389 | TRIM30 modulates Interleukin-22-regulated papillary thyroid Cancer cell migration and invasion by targeting Sox17 for K48-linked Polyubiquitination |
| Q57073678 | The New TNM Staging System for Thyroid Cancer and the Risk of Disease Downstaging |
| Q33679565 | The positive clinical therapeutically effects of Escin on advanced thyroid cancer |
| Q90398775 | The prognostic value of the lymphocyte-to-monocyte ratio for high-risk papillary thyroid carcinoma |
| Q57168326 | Thyroid surgery for differentiated thyroid cancer - recent advances and future directions |
| Q90573581 | Tumour travel tours - Why circulating cancer cells value company |
| Q91783124 | Up-Regulated AKR1C2 is correlated with favorable prognosis in thyroid carcinoma |
| Q47161687 | Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer |
| Q93180980 | Uridine phosphorylase 1 associates to biological and clinical significance in thyroid carcinoma cell lines |
| Q94589373 | [Detection rate of thyroid nodules in routine health check-up and its influencing factors: a 10-year survey of 309 576 cases] |
| Q94475212 | [Endocrine surgery during and after the COVID-19 epidemic: guidelines from AFCE] |
| Q64253343 | circRAPGEF5 Contributes to Papillary Thyroid Proliferation and Metastatis by Regulation miR-198/FGFR1 |
| Q89441860 | mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas |
| Q60301578 | miR-29a-3p inhibits growth, proliferation, and invasion of papillary thyroid carcinoma by suppressing NF-κB signaling via direct targeting of OTUB2 |
Search more.